Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00126815
First received: August 3, 2005
Last updated: December 8, 2011
Last verified: December 2011
  Purpose

Clinical data are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.


Condition
Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Mathematical Modeling Analysis of Serum Prostate Specific Antigen After Radiotherapy

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 1000
Study Start Date: February 2004
Study Completion Date: April 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Clinical data (prostate-specific antigen [PSA] response after radiotherapy) are being used to build a mathematical model to describe the clinical results of radiotherapy for prostate cancer.

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • Prostate cancer treated with radiotherapy +/- hormones

Exclusion Criteria:

  • Prostatectomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00126815

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Matthew Parliament, MD AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00126815     History of Changes
Other Study ID Numbers: NA-15-0002
Study First Received: August 3, 2005
Last Updated: December 8, 2011
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
prostate cancer
prostate specific antigen
radiotherapy
mathematical modeling

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on October 23, 2014